

POSTER PRESENTATION**Open Access**

P75. Genetic engineering of T cells for increased homing to the tumor site

M Idorn*, GH Andersen, HL Larsen, JH van den Berg, Ö Met, P thor Straten

From 1st Immunotherapy of Cancer Conference (ITOC1)
Munich, Germany. 12-14 March 2014

Adoptive cell transfer (ACT) using in vitro expanded T cells from biopsy material represents a highly promising treatment of disseminated cancer. ACT in its present form is rather crude and improvements seem within reach. Recruitment of transferred lymphocytes to the tumor site is a crucial step in ACT efficacy; however, quite few T cells actually reach the tumor site upon administration. In the present pre-clinical study we have genetically engineered T cells aiming at increasing the homing of T cells by matching expression of chemokine receptors on T cells to chemokines secreted by the tumor, thus improving anti-tumor efficacy of ACT. By PCR analysis we found that several malignant melanoma (MM) cell lines showed expression of cytokines CXCL8/IL-8, CXCL12/SDF-1 and CCL2, which was confirmed by ELISA analysis of MM conditioned medium. Taking advantage of mRNA electroporation we successfully transfected T cells with mRNA encoding the chemokine receptors CXCR2 and chimeric receptor CXCR4-R2 on the cell surface, the latter expressing the intracellular region of CXCR2 allowing expression in T cells. Work is in progress, but so far chemokine receptor CXCR2 and chimeric receptor CXCR4-R2 transfected T cells are capable of migrating towards their ligands, CXCL8 and CXCL12 respectively, in *in vitro* transwell migration assays. *In vitro* studies on the transfection and function of the CXCR4 and CCR2-R2 chimeric receptors as well as *in vivo* migration studies have been initiated, and data will be presented at the meeting.

Published: 12 March 2014

doi:10.1186/2051-1426-2-S2-P49

Cite this article as: Idorn et al.: P75. Genetic engineering of T cells for increased homing to the tumor site. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 2):P49.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Center for Cancer Immunotherapy, CCIT, Herlev Universitets Hospital, Herlev
Ringvej 75, 65Q9, 2730 Herlev, Denmark



© 2014 Idorn et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.